NASDAQ: ALPN - Alpine Immune Sciences, Inc.

Lønnsomhet i seks måneder: -88.05%
Sektor: Healthcare

Kampanjeplan Alpine Immune Sciences, Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet

Alpine Immune Sciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, autoimmune/inflammatory disorders, and other diseases.

Flere detaljer
Its product pipeline includes ALPN-101, an inducible T cell costimulator (ICOS)/cluster of differentiation 28 (CD28) antagonist program for the treatment of autoimmune and inflammatory diseases; ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor for the treatment of cancer; and ALPN-303, a dual B cell cytokine antagonist for the treatment of B cell-mediated inflammatory and autoimmune diseases. The company has a collaboration agreement with AbbVie Ireland Unlimited Company for the development of ALPN-101; and Adaptimmune Therapeutics plc to develop next-generation SPEAR T cell products. Alpine Immune Sciences, Inc. was incorporated in 2007 and is headquartered in Seattle, Washington.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

Выручка 0.0017
EBITDA -0.0415
Число акций ао 0.05 млрд
P/S 41.04
P/BV 2.42
EV/EBITDA -1.73
Цена ао 64.4
ISIN US02083G1004
Сайт https://www.alpineimmunesciences.com
Валюта usd
IPO date 2015-06-17
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Prisendring per dag: 0% (7.7)
Prisendring per uke: 0% (7.7)
Prisendring per måned: -88.15% (64.97)
Prisendring over 3 måneder: -1.28% (7.8)
Prisendring over seks måneder: -88.05% (64.43)
Prisendring per år: -24.51% (10.2)
Prisendring over 3 år: -36.52% (12.13)
Prisendring over 5 år: +58.11% (4.87)
Prisendring siden begynnelsen av året: -42.45% (13.38)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 16.49 1
P/BV 2.96 6
P/E 0 0
EV/EBITDA -21.45 0
Total: 3.75

Effektivitet

Navn Betydning Karakter
ROA, % -8.43 0
ROE, % -9.81 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.227 10
Total: 7.8

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 3363.29 10
Lønnsomhet Ebitda, % 5.24 1
Lønnsomhet EPS, % -72.26 0
Total: 4.2
Flere detaljer

Institusjoner Volum Dele, %
Decheng Capital LLC 7083288 10.81
Decheng Capital Management III (Cayman), LLC 6708288 10.23
RA Capital Management, L.P. 4909763 7.49
Lynx1 Capital Management Lp 3813926 5.82
Great Point Partners LLC 3703433 5.65
Paradigm Biocapital Advisors LP 3176743 4.85
Frazier Life Sciences Management, L.P. 3131008 4.78
Blackrock Inc. 3058498 4.67
Cormorant Asset Management, LP 2550000 3.89
Orbimed Advisors LLC. 2535245 3.87



Veileder Stillingstittel Betaling Fødselsår
Dr. Mitchell H. Gold M.D. Executive Chairman & CEO 1.02M 1968 (56 år)
Dr. Stanford Peng M.D., Ph.D. President and Head of Research & Development 940.1k 1971 (53 år)
Mr. Paul Rickey Senior VP, CFO, Treasurer & Secretary 691.1k 1979 (45 år)
Dr. Remy Durand Ph.D. Chief Business Officer N/A 1985 (39 år)
Ms. M. Christina Yi Chief Technology Officer N/A 1977 (47 år)
Temre Johnson Head of IR & Corporate Communications
Dr. Wolfgang Dummer M.D., Ph.D. Chief Medical Officer 1966 (58 år)

Adresse: United States, Seattle. WA, 188 East Blaine Street - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.alpineimmunesciences.com